Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform

Joanna S. Yi, MD, Alex Federation, Jun Qi, PhD, Sirano Dhe-Paganon, PhD, Michael Hadler, MSc, Xiang Xu, PhD, Anthony Varca, Roodolph St. Pierre, Scott A. Armstrong, MD PhD, James E. Bradner

Blood (2014) 124 (21): 4811.

https://doi.org/10.1182/blood.V124.21.4811.4811

Published: 2014

Journal Articles

Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders

William L. Heaton, M.S., Anna M. Eiring, PhD, Nadeem A. Vellore, PhD, Diana Resetca, B.S., Sina Haftchenary, PhD, David Rosa, PhD, Ahmed M. Ali, Anna V. Senina, M.S., Anthony D. Pomicter, M.S., Brent D.G. Page, PhD, Ira L. Kraft, B.S., Kimberly R. Reynolds, M.S., Derek J. Wilson, PhD, Riccardo Baron, PhD, Thomas O'Hare, PhD, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2014) 124 (21): 4816.

https://doi.org/10.1182/blood.V124.21.4816.4816

Published: 2014

Journal Articles

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Danielle C Croucher, MSc, BSc, Zhihua Li, Brent D.G. Page, PhD, Ellen Nong Wei, Patrick T. Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4441.

https://doi.org/10.1182/blood.V122.21.4441.4441

Published: 2013

Journal Articles

Binding Of Immune Serine Proteases To Nucleic Acids Enhances Their Nuclear Localization and Promotes Their Cleavage Of Nucleic Acid-Binding Protein Substrates

Jennifer Whangbo, MD, PhD, Marshall Thomas, Geoffrey McCrossan, Aaron Deutsch, Kimberly Martinod, Michael Walch, MD, Judy Lieberman, MD, PhD

Blood (2013) 122 (21): 3471.

https://doi.org/10.1182/blood.V122.21.3471.3471

Published: 2013

Journal Articles

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Ira L. Kraft, BS, Brent D.G. Page, PhD, Tian Y. Zhang, MD, PhD, Jamshid S. Khorashad, MD, PhD, FRCPath, Nadeem A. Vellore, PhD, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna V. Senina, MS, Matthew S. Zabriskie, BS, Shazia Ahmad, Clinton C. Mason, PhD, Richard Moriggl, PhD, Riccardo Baron, PhD, Thomas O'Hare, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2013) 122 (21): 854.

https://doi.org/10.1182/blood.V122.21.854.854

Published: 2013

Journal Articles

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Ira L Kraft, BS, Anna M. Eiring, PhD, Brent DG Page, BS, Clinton C Mason, PhD, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, David J Anderson, BA, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Johanna Estrada, Matthew S Zabriskie, BS, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 2445.

https://doi.org/10.1182/blood.V120.21.2445.2445

Published: 2012

Journal Articles

Recognition of B2GPI by the Lipoprotein Receptors.

Natalia Beglova, PhD, Chang-Jin Lee, PhD, Alfredo De Biasio, Ph.D.

Blood (2009) 114 (22): 851.

https://doi.org/10.1182/blood.V114.22.851.851

Published: 2009

Journal Articles

Design and Development of Small Molecules for Specific Targeted Therapy of Diffuse Large B-Cell Lymphoma.

Gustavo F. Da Silva, MS, Alex Ghetu, PhD, Leandro Cerchietti, MD, Jose M. Polo, MS, Andrew Coop, PhD, Alexander Mackerell, PhD, Gilbert G. Prive, PhD, Ari Melnick, MD

Blood (2007) 110 (11): 799.

https://doi.org/10.1182/blood.V110.11.799.799

Published: 2007

Journal Articles

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

James Bradner, MD, Edward Greenberg, B.S., Sridevi Ponduru, M.D., Vishal Patel, B.S., Stuart Schreiber, Ph.D., Benjamin Rich, Ph.D., Ralph Mazitschek, Ph.D.

Blood (2007) 110 (11): 800.

https://doi.org/10.1182/blood.V110.11.800.800

Published: 2007

Journal Articles

Exploiting the Tr3 Interaction with Bcl-2 as a Novel Therapeutic Strategy of Cancer and Leukemia Therapy.

Dayong Zhai, PhD, Eduard Sergienko, Ph.D., Shinichi Kitada, M.D., Ph.D., Frederic Luciano, Ph.D., Arnold C. Satterswait, Ph.D., Xiaokun Zhang, B.S., John C. Reed, M.D., Ph.D.

Blood (2006) 108 (11): 256.

https://doi.org/10.1182/blood.V108.11.256.256

Published: 2006

Journal Articles

Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.

Gordon Shore, PhD, Mark Watson, Ph.D., Anne Roulston, Ph.D., Richard Marcellus, Ph.D., Nancy Steenart, Ph.D., Pierre Beauparlant, Ph.D., Sasmita Tripathy, Ph.D., Xavier Billot, Ph.D., Laurent Bélec, Ph.D., Giorgio Attardo, Ph.D., Mai Nguyen, Ph.D., Stephane Acoca, B.Sc., Enrico Purisima, Ph.D, Patricia Pérez-Galan, Ph.D., Dolors Colomer, Ph.D.

Blood (2006) 108 (11): 832.

https://doi.org/10.1182/blood.V108.11.832.832

Published: 2006

Journal Articles

AT-101, a Pan-Inhibitor of Bcl-2 Family Anti-Apoptotic Proteins Antagonizes the Protective Effect Conferred by Nurselike Cells on Primary Chronic Lymphocytic Leukemia (CLL) Cells.

Danelle F. James, MD, Rebecca M. Mervis, B.S., Ruzbeh Mosadeghi, Thomas J. Kipps, M.D, Ph.D.

Blood (2006) 108 (11): 2100.

https://doi.org/10.1182/blood.V108.11.2100.2100

Published: 2006

Journal Articles

R-(−)-Gossypol (AT101) Binds to Bcl-2 Family Proteins and Induces Apoptosis in CLL.

Carlos E. Prada, MD, Januario E. Castro, MD, Dayong Zhai, PhD, Shinichi Kitada, MD, PhD, John C. Reed, MD, PhD, Thomas J. Kipps, MD, PhD

Blood (2005) 106 (11): 2978.

https://doi.org/10.1182/blood.V106.11.2978.2978

Published: 2005

Journal Articles

AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab.

Danelle F. James, MD, Carlos E. Prada, MD, Januario E. Castro, MD, Thomas J. Kipps, MD, PhD

Blood (2005) 106 (11): 2979.

https://doi.org/10.1182/blood.V106.11.2979.2979

Published: 2005

Journal Articles

Affinities of Mcl-1 and Bcl-XL for BH3-Only Proteins Define Distinct Survival Functions at the Outer Mitochondrial Membrane of Multiple Myeloma Cells.

Robert G. Fenton, Michele L. Cramer, Richard B. Thompson, Bin Zhang

Blood (2004) 104 (11): 788.

https://doi.org/10.1182/blood.V104.11.788.788

Published: 2004

NARROW

Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform

Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Binding Of Immune Serine Proteases To Nucleic Acids Enhances Their Nuclear Localization and Promotes Their Cleavage Of Nucleic Acid-Binding Protein Substrates

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Recognition of B2GPI by the Lipoprotein Receptors.

Design and Development of Small Molecules for Specific Targeted Therapy of Diffuse Large B-Cell Lymphoma.

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

Exploiting the Tr3 Interaction with Bcl-2 as a Novel Therapeutic Strategy of Cancer and Leukemia Therapy.

Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.

AT-101, a Pan-Inhibitor of Bcl-2 Family Anti-Apoptotic Proteins Antagonizes the Protective Effect Conferred by Nurselike Cells on Primary Chronic Lymphocytic Leukemia (CLL) Cells.

R-(−)-Gossypol (AT101) Binds to Bcl-2 Family Proteins and Induces Apoptosis in CLL.

AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab.

Affinities of Mcl-1 and Bcl-XL for BH3-Only Proteins Define Distinct Survival Functions at the Outer Mitochondrial Membrane of Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only